LID.L Regulatory News (LID)

7 Jul 2005 07:01

LiDCO Group Plc07 July 2005 Immediate Release 7th July 2005 LiDCO GROUP PLC ("LiDCO" or "the Company") New Veterinary Application for LiDCO's Technology LiDCO Group plc (AIM: LID), the cardiovascular monitoring company, is pleased toannounce the publication of a paper by researchers at the Royal VeterinaryHospital, London validating LiDCO's LiDCOplus Monitor, and in particular theCompany's pulse contour software (PulseCO),for use in the care of horses duringsurgery. The study shows that the software, which is used routinely in humansfor the management of critical care and cardiovascular high risk hospitalpatients, is similarly effective in equine applications. This is the first time that LiDCO's proprietary software, providing continuouspulse contour cardiovascular monitoring, has been demonstrated to be applicablein horses. The paper was entitled: "Use of Lithium dilution and pulse contour analysiscardiac output determination in anaesthetized horses: a clinical evaluation - G.Hallowell & K. Corley, Veterinary Anaesthesia and Analgesia, 2005, 32, 201 -211." The paper concluded that LiDCO's method of pulse contour analysis is arelatively non-invasive and reliable way of monitoring continuous cardiac outputin horses under anaesthesia. The paper also concluded that the ability to easilymonitor continuous cardiac output might decrease morbidity and mortality in theanaesthetized horses. LiDCO believes that these results are comparable with what the Company haspreviously seen from the use of the LiDCOplus technology in humans where theCompany has been able to show that complications, costs and hospital stay can bereduced by an average of 10 days in high risk surgery patients. Dr Kevin Corley, lecturer in Equine Medicine and Critical Care at the RoyalVeterinary Hospital, London, stated: "Lithium dilution cardiac output has proven its worth time and time again in thecare of critically ill horses and foals. The addition of continuous cardiacoutput via pulse contour analysis is a fantastic extra, as it allows us toquickly respond to changes in the haemodynamics of the horse." Dr Terry O'Brien, LiDCO's Chief Executive, commented: "Horses are even more sensitive to anaesthetic drugs than humans and can beseverely and adversely affected by the use of such agents during surgery. Thispaper further validates the accuracy and utility of our products. The use ofLiDCO's minimally invasive continuous cardiovascular monitoring in veterinary,practice should lead to a significant reduction in surgical deaths andcomplications". For further information please contact: LiDCO Group PlcTerry O'Brien - Chief Executive Tel: +44 (0)20 7749 1500Hugh McGarel-Groves - Finance Director Buchanan CommunicationsTim Anderson, Mary-Jane Johnson, James Strong Tel: +44 (0)20 7466 5000 Panmure GordonGrant Harrison, Marcus Jackson Tel: +44 (0)20 7459 3600 Notes for Editors: About LiDCO Plc LiDCO is a UK-based AIM-traded developer, manufacturer and leading supplier ofminimally invasive, computer-based hemodynamic monitoring equipment anddisposables used primarily for the management of critical care andcardiovascular risk hospital patients. Use of LiDCO's technology has been shownto significantly reduce the complications (particularly infections) and costsassociated with major surgery. The technology was invented in the Department ofApplied Physiology based at St Thomas' Hospital, London where the Companymaintains a research base. The Company's manufacturing facility is in Hoxton, London and its currentproducts are: LiDCOplus and PulseCO monitors: computer-based platforms for displaying a rangeof real-time, continuous hemodynamic parameters including cardiac output, oxygendelivery and fluid volume; LiDCO disposables: used in conjunction with the LiDCOplus Monitor accuratelydetermine cardiac output in a minimally-invasive manner. Distribution Network: The Company has achieved registration for its products in 13 markets acrossEurope, the USA, Brazil and Japan. It sells direct to the NHS in the UK, andthrough a worldwide network of specialty critical care distributors. Background to the recently published clinical trial: Better than standard care -(EGDT) improves outcome in high risk surgery patients: The results of a major trial at St George's Hospital, London using LiDCO'sminimally invasive monitoring technology were presented during the 25thInternational Symposium on Intensive Care and Emergency Medicine in Brussels(21st to 25th March). The results have revealed the following: a) Savings in the cost of treating patients amounting to an average of £4,000per patient. Extrapolated nationally, this would equate to a saving of £500million per annum for the NHS b) The monetary saving (£248,000) - resulted from 640 hospital days saved for 62patients, an average of more than 10 bed days per patient c) The savings in cost and hospital days were associated with a significantreduction in medical complications (particularly infections - which were halved) through the use of LiDCO's minimally invasive technology to improve tissueoxygen levels following surgery. This information is provided by RNS The company news service from the London Stock Exchange